SEC Form 3

FORM 3

UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

OMB APPROVAL

OMB Number:	3235-0104
Estimated average burden hours per response:	0.5

INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

1. Name and Address of Reporting Person*	2. Date of Event Requiring Statement (Month/Day/Year)	3. Issuer Name **and** Ticker or Trading Symbol
Menon Vin (Last) (First) (Middle) 30 WATERSIDE PLAZA #36 (Street) NEW YORK NY 10010 (City) (State) (Zip)	12/01/2025	Apimeds Pharmaceuticals US, Inc. [APUS] 4. Relationship of Reporting Person(s) to Issuer (Check all applicable) Director — 10% Owner X Officer (give title below) — Other (specify below) Co-Chief Executive Officer 5. If Amendment, Date of Original Filed (Month/Day/Year) 6. Individual or Joint/Group Filing (Check Applicable Line) X Form filed by One Reporting Person Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Beneficially Owned

1. Title of Security (Instr. 4)	2. Amount of Securities Beneficially Owned (Instr. 4)	3. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	4. Nature of Indirect Beneficial Ownership (Instr. 5)

Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)

1. Title of Derivative Security (Instr. 4)	2. Date Exercisable and Expiration Date (Month/Day/Year)		3. Title and Amount of Securities Underlying Derivative Security (Instr. 4)		4. Conversion or Exercise Price of Derivative Security	5. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	6. Nature of Indirect Beneficial Ownership (Instr. 5)
	Date Exercisable	Expiration Date	Title	Amount or Number of Shares			
Series A Convertible Preferred Stock	(1)	(2)	Common Stock	484,775(3)	(4)	D	

Explanation of Responses:

1. The shares of Series A Convertible Preferred Stock are not convertible at the option of the holder. Each share will automatically convert into shares of Common Stock on the third business day following the later of (i) the effectiveness of stockholder approval of the conversion under NYSE American rules and (ii) NYSE American's approval of the Issuer's new listing application.

2. The Series A Convertible Preferred Stock has no expiration date.

3. Represents 484,775 shares of Common Stock issuable upon conversion as of the date of the event requiring this statement. As adjusted for the Issuer's 1-for-10 reverse stock split effective July 23, 2026, the shares are convertible into 484,775 shares of Common Stock.

4. Each share of Series A Convertible Preferred Stock converts into 20 shares of Common Stock, subject to adjustment under the Certificate of Designation. No additional consideration is payable upon conversion.

/s/ Vin Menon — 11/02/2026

** Signature of Reporting Person — Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

* If the form is filed by more than one reporting person, *see* Instruction 5 (b)(v).

** Intentional misstatements or omissions of facts constitute Federal Criminal Violations *See* 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, *see* Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.